What is the recommended treatment for a patient with recurrent Clostridioides difficile infection?

Treatment of Recurrent Clostridioides difficile Infection

For recurrent C. difficile infection, use fidaxomicin 200 mg twice daily for 10 days as first-line therapy, or oral vancomycin in a tapered and pulsed regimen if fidaxomicin was used initially or is unavailable. 1

First Recurrence Management

The 2021 IDSA/SHEA guidelines represent the most current evidence-based approach 1. Your treatment choice depends on what was used for the initial episode:

If Metronidazole Was Used Initially:

• Vancomycin 125 mg four times daily for 10 days 2
• Alternative: Fidaxomicin 200 mg twice daily for 10 days (preferred if available, as it reduces subsequent recurrence rates from 35.5% to 19.7%) 2

If Vancomycin Was Used Initially:

• Fidaxomicin 200 mg twice daily for 10 days (first choice) 2, 1
• Alternative: Vancomycin tapered and pulsed regimen: 125 mg four times daily for 10-14 days, then twice daily for 7 days, then once daily for 7 days, then every 2-3 days for 2-8 weeks 2

Critical point: Metronidazole should NOT be used for recurrent CDI due to inferior bacteriological cure rates and lower sustained response 3, 4.

Second or Subsequent Recurrences (≥2 Recurrences)

You have four evidence-based options 2:

1. Vancomycin tapered and pulsed regimen (as described above)
2. Vancomycin 125 mg four times daily for 10 days FOLLOWED BY rifaximin 400 mg three times daily for 20 days 2
3. Fidaxomicin 200 mg twice daily for 10 days (standard or extended-pulsed regimen) 1
4. Fecal microbiota transplantation (FMT) - this carries a strong recommendation with moderate quality evidence 2

When to Use FMT

FMT should be offered after at least 2 recurrences (meaning 3 total CDI episodes) when appropriate antibiotic treatments have failed 2. The 2024 BSG/HIS guidelines recommend offering FMT to all patients with two or more recurrences 5. Success rates are approximately 81-94% based on multiple studies 3.

Important safety caveat: Since 2019, FDA safety alerts document transmission of pathogenic E. coli and potential SARS-CoV-2 transmission through FMT, with some deaths reported 1. Ensure rigorous donor screening per current FDA recommendations.

Adjunctive Therapy: Bezlotoxumab

For patients with recurrent CDI within the last 6 months, add bezlotoxumab (10 mg/kg IV single dose) to standard antibiotic therapy 1. This monoclonal antibody against C. difficile toxin B reduces recurrence risk, particularly in:

• Patients with prior CDI recurrence
• Age ≥65 years
• Immunocompromised patients
• Those with severe CDI
• Patients infected with epidemic strain 027 6, 4

Bezlotoxumab does NOT treat active infection—it only prevents recurrence, so must be given WITH antibiotics 7.

Common Pitfalls to Avoid

1. Do NOT repeat metronidazole for recurrent CDI - it has inferior outcomes 3, 4
2. Do NOT perform "test of cure" after treatment unless symptoms persist 8, 5
3. Do NOT delay FMT indefinitely - offer it after 2 recurrences, not after 5-6 episodes 2, 5
4. Do NOT use standard 10-day vancomycin courses repeatedly for multiple recurrences - switch to tapered/pulsed regimens or alternative strategies 2
5. Stop inciting antibiotics immediately if clinically feasible 8, 6

Algorithm Summary

First recurrence:

• Metronidazole used initially → Vancomycin OR Fidaxomicin
• Vancomycin used initially → Fidaxomicin OR Vancomycin taper/pulse

Second recurrence:

• Vancomycin taper/pulse OR
• Vancomycin + rifaximin OR
• Fidaxomicin OR
• FMT (strongly recommended) 2

Consider bezlotoxumab as adjunct in high-risk patients with any recurrence 1, 4

The evidence strongly favors fidaxomicin over vancomycin for reducing subsequent recurrences (moderate quality evidence), though vancomycin remains acceptable when fidaxomicin is unavailable due to cost or formulary restrictions 1, 4. The 2021 ESCMID guidelines similarly elevated fidaxomicin to first-line status and emphasize that treatment strategy should prioritize recurrence risk over disease severity 4.